Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 7.73
(-2.52%)
SEK 7.73
(-2.52%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 142.98 Million SEK | 26.81% |
| 2023 | 112.75 Million SEK | 1.6% |
| 2022 | 110.98 Million SEK | 32.71% |
| 2021 | 83.63 Million SEK | 702.24% |
| 2020 | -13.88 Million SEK | -138.11% |
| 2019 | 36.44 Million SEK | -14.56% |
| 2018 | 42.65 Million SEK | 72.67% |
| 2017 | 24.7 Million SEK | -22.57% |
| 2016 | 31.9 Million SEK | 53.91% |
| 2015 | 20.73 Million SEK | 30.27% |
| 2014 | 15.91 Million SEK | 28.58% |
| 2013 | 12.37 Million SEK | -80.81% |
| 2012 | 64.5 Million SEK | -61.92% |
| 2011 | 169.4 Million SEK | 46.08% |
| 2010 | 115.96 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 41.47 Million SEK | 51.9% |
| 2024 Q3 | 27.3 Million SEK | 60.81% |
| 2024 Q2 | 16.97 Million SEK | -43.11% |
| 2024 Q1 | 29.84 Million SEK | -18.08% |
| 2023 Q1 | 31.93 Million SEK | -19.32% |
| 2023 FY | 112.75 Million SEK | 1.6% |
| 2023 Q4 | 36.42 Million SEK | 68.93% |
| 2023 Q3 | 21.56 Million SEK | -5.56% |
| 2023 Q2 | 22.83 Million SEK | -28.51% |
| 2022 Q4 | 39.58 Million SEK | 139.11% |
| 2022 FY | 110.98 Million SEK | 32.71% |
| 2022 Q3 | 16.55 Million SEK | -4.25% |
| 2022 Q2 | 17.28 Million SEK | -55.11% |
| 2022 Q1 | 38.51 Million SEK | 37.62% |
| 2021 Q1 | 12.43 Million SEK | 11.71% |
| 2021 Q2 | 11.06 Million SEK | -11.03% |
| 2021 Q3 | 32.15 Million SEK | 190.72% |
| 2021 FY | 83.63 Million SEK | 702.24% |
| 2021 Q4 | 27.98 Million SEK | -12.96% |
| 2020 Q1 | 6.41 Million SEK | -34.13% |
| 2020 Q3 | 5.71 Million SEK | 115.38% |
| 2020 Q4 | 11.12 Million SEK | 94.73% |
| 2020 Q2 | -37.14 Million SEK | -678.81% |
| 2020 FY | -13.88 Million SEK | -138.11% |
| 2019 Q4 | 9.74 Million SEK | 14.95% |
| 2019 Q1 | 8.31 Million SEK | -25.33% |
| 2019 FY | 36.44 Million SEK | -14.56% |
| 2019 Q2 | 9.88 Million SEK | 18.78% |
| 2019 Q3 | 8.47 Million SEK | -14.21% |
| 2018 Q3 | 11.86 Million SEK | 37.26% |
| 2018 FY | 42.65 Million SEK | 72.67% |
| 2018 Q4 | 11.14 Million SEK | -6.1% |
| 2018 Q2 | 8.64 Million SEK | -21.72% |
| 2018 Q1 | 11.04 Million SEK | 72.21% |
| 2017 FY | 24.7 Million SEK | -22.57% |
| 2017 Q4 | 6.41 Million SEK | -19.27% |
| 2017 Q1 | 4.71 Million SEK | -74.32% |
| 2017 Q2 | 5.63 Million SEK | 19.68% |
| 2017 Q3 | 7.94 Million SEK | 40.91% |
| 2016 FY | 31.9 Million SEK | 53.91% |
| 2016 Q1 | 4.37 Million SEK | 20.65% |
| 2016 Q2 | 4.62 Million SEK | 5.88% |
| 2016 Q3 | 4.63 Million SEK | 0.09% |
| 2016 Q4 | 18.34 Million SEK | 295.94% |
| 2015 Q4 | 3.62 Million SEK | -50.55% |
| 2015 Q3 | 7.32 Million SEK | 88.45% |
| 2015 Q2 | 3.88 Million SEK | -34.02% |
| 2015 Q1 | 5.89 Million SEK | 78.36% |
| 2015 FY | 20.73 Million SEK | 30.27% |
| 2014 Q4 | 3.3 Million SEK | -8.15% |
| 2014 Q2 | 4.06 Million SEK | -17.9% |
| 2014 Q3 | 3.59 Million SEK | -11.47% |
| 2014 Q1 | 4.94 Million SEK | 14.24% |
| 2014 FY | 15.91 Million SEK | 28.58% |
| 2013 Q1 | -1 Million SEK | -103.42% |
| 2013 Q4 | 4.33 Million SEK | 10.2% |
| 2013 FY | 12.37 Million SEK | -80.81% |
| 2013 Q3 | 3.93 Million SEK | -22.43% |
| 2013 Q2 | 5.06 Million SEK | 605.79% |
| 2012 Q1 | 13.31 Million SEK | -59.86% |
| 2012 Q4 | 29.31 Million SEK | 380.54% |
| 2012 Q2 | 15.77 Million SEK | 18.48% |
| 2012 Q3 | 6.1 Million SEK | -61.32% |
| 2012 FY | 64.5 Million SEK | -61.92% |
| 2011 Q1 | 47.66 Million SEK | 26.49% |
| 2011 FY | 169.4 Million SEK | 46.08% |
| 2011 Q2 | 42.68 Million SEK | -10.45% |
| 2011 Q3 | 45.89 Million SEK | 7.53% |
| 2011 Q4 | 33.16 Million SEK | -27.75% |
| 2010 Q2 | 27.01 Million SEK | 0.0% |
| 2010 FY | 115.96 Million SEK | 0.0% |
| 2010 Q3 | 32.45 Million SEK | 20.13% |
| 2010 Q4 | 37.68 Million SEK | 16.12% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alzinova AB (publ) | 36.39 Million SEK | -292.865% |
| Amniotics AB (publ) | 29.07 Million SEK | -391.838% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -875.821% |
| BioArctic AB (publ) | 89.62 Million SEK | -59.536% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 90.557% |
| Camurus AB (publ) | 1.05 Billion SEK | 86.506% |
| Cantargia AB (publ) | 290.01 Million SEK | 50.697% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -553.058% |
| Genovis AB (publ.) | 88.19 Million SEK | -62.122% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | -24.258% |
| Mendus AB (publ) | 129.13 Million SEK | -10.725% |
| Kancera AB (publ) | 63.07 Million SEK | -126.686% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -2490.814% |
| LIDDS AB (publ) | 27.75 Million SEK | -415.231% |
| Lipum AB (publ) | 37.3 Million SEK | -283.271% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1871.147% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | -5.206% |
| NextCell Pharma AB | -576.01 Thousand SEK | 24923.313% |
| OncoZenge AB (publ) | 15.9 Million SEK | -799.007% |
| Saniona AB (publ) | 1.07 Million SEK | -13176.416% |
| Simris Alg AB (publ) | 38.64 Million SEK | -270.03% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 55.526% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 60.017% |
| Xintela AB (publ) | 57.31 Million SEK | -149.471% |
| Ziccum AB (publ) | 27.87 Million SEK | -412.903% |
| AcouSort AB (publ) | 25.87 Million SEK | -452.585% |
| Active Biotech AB (publ) | 44.8 Million SEK | -219.103% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -404.785% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -771.819% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1867.35% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 21.321% |
| CombiGene AB (publ) | 44.14 Million SEK | -223.91% |
| Intervacc AB (publ) | 79.78 Million SEK | -79.215% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 53.438% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -235.398% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -708.613% |
| Corline Biomedical AB | 30.16 Million SEK | -373.969% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -146.398% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -71.923% |
| Aptahem AB (publ) | 10.01 Million SEK | -1328.022% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | -6.157% |
| Fluicell AB (publ) | 28.61 Million SEK | -399.658% |
| Biovica International AB (publ) | 133.72 Million SEK | -6.929% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -622.521% |
| Abliva AB (publ) | 27.86 Million SEK | -413.124% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 26.105% |
| 2cureX AB (publ) | 36.51 Million SEK | -291.552% |
| I-Tech AB | 40.14 Million SEK | -256.15% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 83.363% |
| Cyxone AB (publ) | 28.21 Million SEK | -406.794% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -30.739% |
| Biosergen AB | 26.8 Million SEK | -433.354% |
| Nanologica AB (publ) | 69.88 Million SEK | -104.597% |
| SynAct Pharma AB | 224.49 Million SEK | 36.308% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -223.676% |
| BioInvent International AB (publ) | 441.4 Million SEK | 67.606% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -496.917% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 50.651% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1720.037% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | -28.917% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -872.701% |